High Potency Active Pharmaceutical Ingredient (HPAPI) Market to Reach US$25.1 bn by 2023 as Oncology Therapeutics Advance

14 Jul, 2016, 08:30 ET from Transparency Market Research

ALBANY, New York, July 14, 2016 /PRNewswire/ --

The global high potency active pharmaceutical ingredient (HPAPI) market is expected to reach US$25.1 bn by the end of 2023. This market was recorded at US$12.6 bn in 2014 and is exhibiting a CAGR of 7.80% between 2015 and 2023, according to a research report released by Transparency Market Research. The report, titled "High Potency Active Pharmaceutical Ingredient (HPAPI) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023," takes into account multiple factors that influence this market at present, as well as those that are expected to influence it in the near future.

Get Research PDF for more Professional and Technical Industry Insights: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=748

Targeted therapy is a relatively new aspect of cancer treatment. It helps medical professionals make use of new drugs that can specifically target cancer cells while doing little to no damage to healthy cells. It is an increasingly popular field of research and development in the medical industry and the global high potency active pharmaceutical ingredient (HPAPI) market forms a major aspect of it. APIs or HPAPIs are heavily used in targeted cancer therapy.

The primary driver for the global HPAPI market, therefore, is the advancement made in its use in the field of oncology. The report segments the global HPAPI market in terms of therapeutic areas into oncology, cardiovascular, anti-diabetic, musculoskeletal, central nervous system, and others. Within these, the market is led by the segment of oncology therapeutics, which occupy over 50% of the market currently. Manufacturers are improving their capacities in order to meet the increasing demand for HPAPIs in oncology. The developments regarding HPAPIs in oncology are also boosting the global HPAPI market and allowing it to gain a higher percentage of the global pharmaceutical ingredients market, although it currently holds a very small share in it.

Other segments of the global HPAPI market are made by the report according to various criteria, including synthesis, manufacturer type, product type, and geography.

In terms of the types of manufacturers, the global HPAPI market is segmented into third-party manufacturers and in-house manufacturers. In terms of product types, the market is divided into generic HPAPIs and innovative HPAPIs, while it is divided into synthetic and biotech HPAPIs on the basis of synthesis.

Browse Research Report with ToC & Free Analysis: http://www.transparencymarketresearch.com/high-potency-active-pharmaceutical-Ingredients-market.html

A major restraint on the global HPAPI market is the pending expiration of major patents, including the ones for Rituxan, Remicade, Humira, Erbitux, Synagis, Herceptin, and Avastin.

The report's geographical assessment of the global HPAPI market shows the majority of the market and player base to be housed in North America and Europe. Earlier situations and legal restrictions had discouraged North American players in the HPAPI market from getting outsourcing support from Asian countries. But legal implications have smoothened out over time, which has allowed a larger number of key players to spread their base across Asia Pacific. As a result, this region is expected to show the fastest growth rate in the global HPAPI market over the given forecast period.

The key players in the global high potency active pharmaceutical ingredients market are WuXi AppTec, Sigma-Aldrich Co. LLC, Pfizer, Inc., Sandoz International GmbH, Novasep, Lonza Group, Dr. Reddy's Laboratories, Cambrex Corporation, and Alkermes plc.

Browse Research Analysis Blog: http://www.tmrblog.com/2016/03/high-potency-active-pharmaceutical-ingredients-market.html

Key segments of the Global High Potency Active Pharmaceutical Ingredient (HPAPI) Market 

By Therapeutic Areas 

  • Oncology
  • Anti-diabetic
  • Cardiovascular
  • Central nervous system
  • Musculoskeletal
  • Others

By Type of Synthesis    

  • Synthetic HPAPI
  • Biotech HPAPI

By Type of Manufacturers    

  • Captive or In-house manufacturers
  • Merchant or Third party manufacturers

By Type of Market    

  • Innovative  
  • Generic

Major regions analyzed under this research report are: 

  • Europe
  • North America
  • Asia Pacific
  • Rest of the World

Browse Other Latest Research Reports:  

Active Pharmaceutical Ingredients Market Expected to Reach US$ 21.9 Bn Globally in 2023: 

http://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html

Looming Patent Expiry of Blockbuster Drugs to Negatively Influence Demand for Hospital Pharmaceuticals Market Globally: 

http://www.transparencymarketresearch.com/hospital-pharmaceuticals-market.html

Global Antidiabetics Market: http://www.transparencymarketresearch.com/antidiabetics-market.html

About Us: 

Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

US Office Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Blog: http://www.tmrblog.com/

SOURCE Transparency Market Research